期刊
JOURNAL OF INFECTIOUS DISEASES
卷 215, 期 12, 页码 1807-1815出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jix209
关键词
human monoclonal antibody; MERS-CoV; common marmoset
资金
- CAMS Innovation Fund for Medical Sciences [2016-I2M-1-014]
- Chinese National Major S T Project [2013ZX10004-101]
- National Key Plan for Scientific Research and Development of China [2016YFD0500300]
- National Science Foundation of China from the National Science Foundation [31500757, 31400787]
Middle East respiratory syndrome coronavirus (MERS-CoV) infection in humans is highly lethal, with a fatality rate of 35%. New prophylactic and therapeutic strategies to combat human infections are urgently needed. We isolated a fully human neutralizing antibody, MCA1, from a human survivor. The antibody recognizes the receptor-binding domain of MERS-CoV S glycoprotein and interferes with the interaction between viral S and the human cellular receptor human dipeptidyl peptidase 4 (DPP4). To our knowledge, this study is the first to report a human neutralizing monoclonal antibody that completely inhibits MERS-CoV replication in common marmosets. Monotherapy with MCA1 represents a potential alternative treatment for human infections with MERS-CoV worthy of evaluation in clinical settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据